Partial or complete lack of dihydropyrimidine dehydrogenase (DPD) enzyme functionality can increase the risk of severe drug toxicity during treatment with fluoropyrimidines (5-FU, capecitabine, tegafur). Understanding DPYD gene status and its impact on drug metabolism is a rapidly growing focus area in clinical research.
The VeriDose® DPYD Panel targets a set of 9 DPYD variants associated with an increased risk of severe toxicity, including the 5 variants recommended by the European Medical Agency and the 4 variants of primary relevance as noted by the Clinical Pharmacogenetics Implementation Consortium. The single well panel can be run either alone or side-by-side with other genotyping panels.
|Product||# of Samples||Format||Catalog #|
|VeriDose DPYD Panel Set – CPM (2x96)||192||96 CPM||13366F|
|VeriDose DPYD Panel Set – CPM (10x96)||960||96 CPM||13330F|
|VeriDose DPYD Panel Set – CPM (10x384)||3,840||384 CPM||13331D|